Objective:

To apply the monoclonal antibody technique for HER2/neu, in tumors of indigenous natives of Peru with breast cancer, as well as to correlate molecular overexpression with global survival.

Patients and methods:

Experimental, prospective and analytical study. 23 biological samples of tumors from indigenous Andean patients from Arequipa, with a definitive diagnosis of breast adenocarcinoma, were evaluated. HER2/neu expression was determined by immunohistochemistry with monoclonal antibodies.

Results:

43.4% (10 cases) were positive for receptor overexpression. The negative cases were 56.6%. The overall survival of the patients at 3 years was 69.9% when the tumors had overexpressed HER2/neu and 84.6% for the negative ones, showing a statistically significant difference (p = 0.017)

Conclusions:

The immunohistochemical technique in Andean indigenous mammary tumors can be applied following world protocols. Likewise, there was a correlation between the overexpression of the HER2 / neu receptor with lower overall survival. The main benefit of this technique is to justify the use of biological therapy with monoclonal antibodies, according to the molecular profile, in the native population of Arequipa, in a hospital near their residence.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )